ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Integrated DNA Technologies Debuts Collab Network

Inaugural program fuels new collaborations in genomics, with founding members including next generation sequencing providers such as Complete Genomics, Element Biosciences, and Ultima Genomics, along with other individual collaborators

With a mission to accelerate the pace of genomics, Integrated DNA Technologies (IDT) has launched Collab Network, a first-of-its-kind IDT program aimed at uniting researchers and industry partners under a single, impactful research network to foster learning, collaboration and future technology development. The Collab Network Program was officially unveiled at the 2023 Advances in Genome Biology and Technology General Meeting taking place Feb. 6 to Feb. 9 in Hollywood, Fla.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230207005228/en/

The IDT Collab Network provides members access to new opportunities to advance their research through the support of IDT’s global network. The program was established to bolster collaborations to drive new discoveries, spotlight research from around the world, drive the development of new products, and invest in the next generation of researchers. Collab Network members—which are comprised of cutting-edge companies focused on next generation sequencing, automation partners, as well as genomics pioneers whose research spans infectious disease, viral surveillance, oncology, rare disease and more—are not only experts within their own domain but also educators within the research community. Members to date include: Catalytic Data Science, Complete Genomics (a subsidiary of MGI Tech Co., Ltd.), Element Biosciences, Geneseeq Technology, Helix, MLL Munich Leukemia Laboratory, Novogene, Opentrons Robotics, PerkinElmer, Psomagen, Singular Genomics, Sistemas Genomicos, Ultima Genomics, as well as individual collaborators from industry and academia.

“Now more than ever, collaborating with research partners who are united in a shared mission to accelerate the pace of genomics is becoming increasingly critical to advancing the future of medicine,” said Demaris Mills, president at IDT. “Our current roster of Collab Network members represents some of the industry’s most disruptive companies who are leading the charge in technology and innovation, as well as genomics developers who are well-respected in their areas of research. By combining our technologies and know-how, together we can unlock new scientific discoveries to rapidly transition from bench to breakthrough.”

To help researchers accelerate scientific discoveries in cancer research, infectious disease, rare disease and more, IDT delivers proprietary technologies for genomics applications such as next generation sequencing, CRISPR genome editing, synthetic biology, digital PCR, and RNA interference. Programs like Collab Network are helping to connect researchers with trusted service providers to advance new discoveries, foster case study development and invest in the next generation of industry leaders.

IDT seeks to continue expanding its Collab Network with additional researchers and institutions across all application areas. The program will also feature research grant opportunities, with more details announced later this year. For additional information on the Collab Network, view a full list of members, or to submit a request to join the group, visit https://www.idtdna.com/pages/about/collabs-network/collaborators.

About IDT

Integrated DNA Technologies, Inc. (IDT) develops, manufactures, and markets nucleic acid products for the life sciences industry. IDT has developed proprietary technologies for genomics applications such as next generation sequencing, CRISPR genome editing, synthetic biology, digital PCR, and RNA interference. Through its GMP* services, IDT manufactures products used by scientists researching many forms of cancer and most inherited and infectious diseases. IDT is widely recognized as the industry leader in custom nucleic acid manufacture, serving over 130,000 life sciences researchers. IDT was founded in 1987 and has its manufacturing headquarters in Coralville, Iowa, USA, with additional manufacturing sites in San Diego, California, USA; Research Triangle Park, North Carolina, USA; Ann Arbor, Michigan, USA; Leuven, Belgium; and Singapore. For more information, visit www.idtdna.com and follow the company on Twitter, LinkedIn, Facebook, YouTube, and Instagram.

Disclaimer: RUO — For research use only. Not for use in diagnostic procedures. Unless otherwise agreed to in writing, IDT does not intend these products to be used in clinical applications and does not warrant their fitness or suitability for any clinical diagnostic use. *GMP refers to products manufactured under ISO 13485: 2016 QMS. Purchaser is solely responsible for all decisions regarding the use of these products and any associated regulatory or legal obligations.

Contacts

Kristina Sarenas

Manager of PR

800-328-2661 (USA & Canada)

+1 319-626-8400 (outside USA)

idtpr@idtdna.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.